FDA Approves Nivolumab in Locally Advanced or Metastatic Bladder Cancer

February 2nd, 2017 – On February 2, 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to nivolumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with a platinum-containing chemotherapy. Approval was based on … (leggi tutto)